Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-25
    E.g., 2018-06-25

Articles

51062 items
12:00 AM, Jul 27, 2000  |  BC Extra | Company News

Millennium completes Cambridge acquisition

MLNM completed its acquisition of the computational chemistry company Cambridge Discovery Chemistry, which had been a subsidiary of Oxford Molecular (LSE:OMG) (see BioCentury Extra, Tuesday July 6)....
12:00 AM, Jul 27, 2000  |  BC Extra | Company News

Peptide and Cantab in merger talks

The vaccines companies Peptide (LSE:PTE) and Cantab (LSE:CTB) said they are in merger talks that could lead to the acquisition of PTE....
12:00 AM, Jul 27, 2000  |  BC Extra | Company News

Ethicon Endo-Surgery returns rights to Genetronics

Johnson & Johnson subsidiary Ethicon Endo-Surgery (Cincinnati, Ohio) terminated a 1998 development and supply agreement with Genetronics (GEB; TSE:GEB) without cause. The deal covered GEB's electroporation drug delivery system for cancer treatment. GEB said it...
12:00 AM, Jul 27, 2000  |  BC Extra | Top Story

Sangstat settles with Novartis

SANG said it settled cyclosporine patent litigation with Novartis (SWX:NOVN; NVS) that had been ongoing in the U.S. and U.K. The settlement comes two weeks after SANG withdrew from the market its SangCya generic cyclosporine...
12:00 AM, Jul 27, 2000  |  BC Extra | Company News

ValiGen acquires Infogen

Drug discovery company ValiGen (Rotterdam, the Netherlands), acquired Infogen (Berlin, Germany) in a stock deal. Infogen specializes in genetic risk assessment and disease management using its database of phenotypic profiles and genetic variants, primarily in...
12:00 AM, Jul 27, 2000  |  BC Extra | Financial News

Applied Biosystems meets Street EPS

PEB reported EPS of $0.26 and $0.86 for the fourth quarter and fiscal year ended June 30, meeting the consensus EPS estimates. Fourth quarter revenues were $391.8 million, a 21 percent increase over the $323.5...
12:00 AM, Jul 27, 2000  |  BC Extra | Financial News

Antisoma to raise 8.7 million

Antisoma (LSE:ASM; EASD:ASOM), a cancer drug development company, said it plans to raise 8.7 million ($13.1 million) through a placing of 7.7 million shares at 117p a share. Nomura is the broker....
12:00 AM, Jul 27, 2000  |  BC Extra | Clinical News

Boston Life Sciences reports Phase III data

BLSI said that a blinded analysis of SPECT scans from a Phase III trial showed that Altropane provided 75 percent sensitivity in detecting Parkinson's disease (PD), 86 percent specificity in ruling out a diagnosis of...
12:00 AM, Jul 27, 2000  |  BC Extra | Financial News

Serono raises $900 million

Serono (SWX:SEO; SRA) closed its previously announced offering of 973,336 million shares sold as ADSs on the New York Stock Exchange (see BioCentury Extra, Thursday June 22). The shares were sold at CHF 1,550...
12:00 AM, Jul 27, 2000  |  BC Extra | Financial News

IPO triumvirate

Three IPOs priced on Thursday. Enzymes developer Genencor (GCOR) raised $126 million through the sale of 7 million shares at $18. The deal, which has a 1.05 million-share overallotment, was underwritten by Merrill Lynch; Chase...

Pages